Section Arrow
OCS.NASDAQ
- Oculis Holding AG
Quotes are at least 15-min delayed:2025/01/13 06:48 EST
Last
 21.15
+2.45 (+13.10%)
Day High 
21.38 
Prev. Close
18.7 
1-M High
18.7201 
Volume 
349.79K 
Bid
21.7
Ask
21.83
Day Low
20.25 
Open
20.35 
1-M Low
16.34 
Market Cap 
784.37M 
Currency USD 
P/E 62.62 
%Yield -- 
10-SMA 17.41 
20-SMA 17.16 
50-SMA 16.4 
52-W High 18.7201 
52-W Low 10.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.65/-1.97
Enterprise Value
784.80M
Balance Sheet
Book Value Per Share
2.50
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/13 06:48 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.